GlassScriptPhysician profile
Timothy J Panella
NPI 1801908223
$13,213.35
in general payments reported to CMS, 2019-2025
76 companies · $2,727 in 2025
The $2,727 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,320 · 2020: $555 · 2021: $782 · 2022: $1,432 · 2023: $2,470 · 2024: $2,928 · 2025: $2,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,649 · Education: $276 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,648.67 |
| Education | $276.39 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,436.76 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,205.78 | 2019-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $1,165.82 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Regeneron Healthcare Solutions, INC. | $763.46 | 2019-2025 | Libtayo |
| Genentech USA, INC. | $685.58 | 2019-2025 | Phesgo, Perjeta, Venclexta |
| Genzyme Corporation | $607.37 | 2019-2025 | |
| Pfizer INC. | $594.99 | 2019-2025 | |
| Amgen INC. | $573.50 | 2019-2025 | Xgeva, Vectibix, Nplate |
| Gilead Sciences, INC. | $479.43 | 2019-2025 | Trodelvy |
| Astellas Pharma US INC | $437.83 | 2019-2025 | Padcev, Cresemba, Vyloy |
| Astrazeneca Pharmaceuticals LP | $324.03 | 2019-2025 | Enhertu |
| Janssen Biotech, INC. | $295.06 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Celgene Corporation | $291.84 | 2019-2025 | Reblozyl, Onureg |
| Daiichi Sankyo INC. | $262.44 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Lilly USA, LLC | $255.20 | 2019-2025 | Retevmo, Verzenio, Jaypirca |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $230.65 | 2019-2025 | |
| Incyte Corporation | $206.27 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $184.90 | 2019-2025 | Ninlaro, Iclusig |
| Abbvie INC. | $176.45 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $164.59 | 2019-2024 | Ultomiris |
| Seagen INC. | $159.02 | 2019-2023 | Tukysa |
| Aveo Pharmaceuticals, INC. | $157.92 | 2023-2025 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $153.50 | 2019-2024 | Onivyde, Tazverik |
| Puma Biotechnology, INC. | $135.13 | 2021-2025 | |
| Glaxosmithkline, LLC. | $118.79 | 2021-2025 | Ojjaara, Zejula |
| Exelixis INC. | $118.27 | 2020-2025 | Cabometyx |
| Jazz Pharmaceuticals INC. | $114.62 | 2019-2025 | Zepzelca |
| Emd Serono, INC. | $107.82 | 2019-2025 | Bavencio |
| Immunocore Limited | $98.28 | 2023-2025 | Kimmtrak |
| Tempus Ai, INC | $96.26 | 2024-2025 | Xt Cdx |
| Deciphera Pharmaceuticals INC. | $89.78 | 2022-2025 | Qinlock, Romvimza |
| Rigel Pharmaceuticals, INC. | $87.80 | 2019-2024 | Tavalisse, Rezlidhia |
| Beigene USA, INC. | $84.59 | 2021-2024 | Brukinsa |
| Kyowa Kirin, INC. | $73.36 | 2019-2025 | |
| Array Biopharma INC | $71.63 | 2019-2023 | Mektovi, Braftovi, Lorbrena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.87 | 2019-2021 | |
| Regeneron Pharmaceuticals, INC. | $70.60 | 2022-2025 | Libtayo |
| Myriad Genetic Laboratories, INC. | $69.01 | 2021-2024 | Myrisk |
| Acrotech Biopharma INC. | $64.07 | 2023-2024 | Beleodaq |
| Bayer Healthcare Pharmaceuticals INC. | $61.39 | 2019-2023 | |
| Taiho Oncology, INC. | $60.55 | 2021-2025 | |
| Iovance Biotherapeutics, INC. | $55.54 | 2025 | Amtagvi |
| Agios Pharmaceuticals, INC. | $48.84 | 2019-2025 | Pyrukynd |
| Karyopharm Therapeutics INC. | $47.45 | 2023-2024 | Xpovio |
| Beone Medicines USA, INC. | $42.64 | 2025 | Brukinsa, Tevimbra |
| Blueprint Medicines Corporation | $42.08 | 2024-2025 | Ayvakit |
| Sun Pharmaceutical Industries INC. | $41.29 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $40.55 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $32.54 | 2022-2023 | Amvuttra |
| Springworks Therapeutics, INC. | $31.70 | 2025 | Ogsiveo |
| Adaptive Biotechnologies Corporation | $31.62 | 2023-2024 | Clonoseq |
| Mirati Therapeutics, INC. | $29.35 | 2023 | Krazati |
| Foundation Medicine, INC. | $27.66 | 2019-2021 | |
| Geron Corporation | $25.07 | 2025 | Rytelo |
| Kite Pharma, INC. | $24.61 | 2024 | Yescarta |
| Tersera Therapeutics LLC | $24.58 | 2024 | Xermelo |
| Genmab U.S., INC. | $24.01 | 2024 | Epkinly |
| Macrogenics, INC. | $23.23 | 2022 | |
| Acceleron Pharma, INC. | $19.15 | 2021 | |
| Sobi, INC | $18.83 | 2024 | |
| Akcea Therapeutics, INC. | $18.29 | 2019 | |
| Tg Therapeutics, INC. | $18.04 | 2021 | |
| Adc Therapeutics America, INC. | $17.54 | 2025 | |
| G1 Therapeutics, INC. | $17.03 | 2022 | |
| Syndax Pharmaceuticals, INC. | $16.36 | 2025 | |
| Pharmacosmos Therapeutics INC. | $15.24 | 2023 | Monoferric |
| Acera Surgical, INC. | $14.31 | 2025 | Restrata Wound Matrix |
| Azurity Pharmaceuticals, INC. | $14.08 | 2025 | Danziten, Vivimusta |
| Coherus Oncology, INC. | $14.04 | 2021 | |
| Aadi Bioscience, INC. | $14.02 | 2023 | Fyarro |
| Morphosys, US INC. | $13.04 | 2022 | |
| Aerin Medical INC. | $5.41 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$25,980.21 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Panella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.